Biofrontera AG (XTRA: B8FK)
Health Care · Pharmaceuticals · DE
€2.43
+0.83% today · -12.6% 1Y
Biofrontera AG (XTRA: B8FK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $17.24M and employs 69 people.
Over the last twelve months the share price has lost 12.6%, trading between 2.21 and 2.96.
Tweenvest scores Biofrontera AG across four factors: quality 56/100, value 60/100, growth 0/100. Its strongest factor is value.
B8FK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.24M
- Revenue (TTM)
- $15.71M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- -0.23
- 52-week high
- €2.96
- 52-week low
- €2.21
- Avg volume (3M)
- —
- Shares outstanding
- 6.08M
- Employees
- 69
- Next earnings
- —
About Biofrontera AG
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
- ISIN
- DE000A4BGGM7
- Founded
- 1997
- Listed since
- Oct 31, 2006
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.46 | -0.04% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.89 | -0.05% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $155.63 | +3.30% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.40 | +1.54% |
Figures last refreshed Aug 18, 2026.